PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-304.05%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.69%
Well above RVPH's 125.07% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
176.34%
AP growth well above RVPH's 101.70%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
-34.25%
Negative yoy usage while RVPH is 159.63%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
198.30%
Well above RVPH's 81.82%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
56.08%
Operating cash flow growth 1.25-1.5x RVPH's 38.83%. Bruce Berkowitz might see better working capital management or consistent margin advantages.
100.00%
CapEx growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
42.27%
Debt repayment at 75-90% of RVPH's 52.51%. Bill Ackman urges more debt clearance to match competitor’s lower leverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.